Abstracts Archive - Page 1046 of 2425 - ACR Meeting Abstracts

Abstract Number: 621 • 2018 ACR/ARHP Annual Meeting
Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids
Shintaro Hirata¹, Kei Araki¹, Hiroki Kohno¹, Kazutoshi Yukawa¹, Tadahiro Tokunaga¹, Tatsuomi Kuranobu¹, Katsuhiro Oi¹, Yusuke Yoshida¹, Tomohiro Sugimoto¹, Keisuke Oda^1,2, Takaki Nojima^1,3 and Eiji Sugiyama¹, ¹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ²Hiroshima Clinic, Hiroshima, Japan, ³Nojima Internal Medicine Clinic, Hiroshima, Japan
Background/Purpose: Short-term glucocorticoids (GCs) along with methotrexate (MTX) has been recommended for newly onset patients with rheumatoid arthritis (RA) in EULAR recommendation 2016. However, it…
Abstract Number: 622 • 2018 ACR/ARHP Annual Meeting
DMARD Withdrawal in RA Patients Achieving Therapeutic Response with Certolizumab Pegol Combined with Dmards: Results from a Canadian Randomized Study
Janet E. Pope¹, Emmanouil Rampakakis², Julie Vaillancourt², Eric Grant³, Louis Bessette⁴, Juris Lazovskis⁵, Boulos Haraoui⁶ and John S. Sampalis⁷, ¹Department of Medicine, University of Western Ontario, London, ON, Canada, ²JSS Medical Research, Montreal, QC, Canada, ³Private Practice, Saint John, NB, Canada, ⁴Laval University, Québec, QC, Canada, ⁵Riverside Professional Centre, Sydney, NS, Canada, ⁶Institut de Rhumatologie de Montreal, Montreal, QC, Canada, ⁷McGill University, Montreal, QC, Canada
Background/Purpose: The efficacy and safety of certolizumab pegol (CZP) in the treatment of adult patients with moderate to severe rheumatoid arthritis (RA), when administered either…
Abstract Number: 623 • 2018 ACR/ARHP Annual Meeting
Step-Down-Bridge Versus Tight-Step-up Therapy in Patients with Early Rheumatoid Arthritis Lacking Poor Prognostic Factors: An Economic Point of View
Sofia Pazmino¹, René Westhovens², Veerle Stouten¹, Johan Joly³, Kristien Van der Elst³, Diederik De Cock⁴ and Patrick Verschueren³, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ³University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: In the Care in early RA (CareRA) trial, COBRA Slim, a combination of methotrexate (MTX) with a moderate-dose prednisone step-down-bridge scheme, showed a positive…
Abstract Number: 624 • 2018 ACR/ARHP Annual Meeting
Easy Accessibility of Biologics and Its Impact on Disease Activity and Quality of Life in Kuwaiti Patients with Rheumatoid Arthritis
Adeeba Al-Herz¹, Khulood Saleh², Adel Al-Awadhi³, Waleed Al-Kandari², Eman Hasan⁴, Aqeel Ghanem⁵, Yaser Ali⁵, Hebah Alhajeri⁶, Sawsan Hayat⁵, Ali Aldei⁷, Mohammad Hussain⁴, Ibrahim Nahar⁵, Fatemah Abutiban⁸, Ahmad Alenizi⁸, Khaled Mokaddem¹, Ahmad Khadrawy², Ammad Fazal², Agaz Zaman⁵, Ghada Mazloum⁵, Youssef Bartella¹, Sally Hamed¹, Ramia Alsouk⁸ and Ahmed Al-Saber⁹, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Rheumatology, Farwania Hospital, Farwania, Kuwait, ³Faculty of Medicine, Kuwait, Kuwait, ⁴Al-Amiri Hospital, Kuwait city, Kuwait, ⁵Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ⁶Division of Rheumatology, Mubarak Al-Kabeer Hospital, hawalli, Kuwait, ⁷Rheumatology, Al-Amiri Hospital, Kuwait City, Kuwait, ⁸Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁹Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: Prescribing biologics for patients with rheumatoid arthritis (RA) may be restricted by many factors other than the physician’s clinical judgment. In Kuwait, patients with…
Abstract Number: 625 • 2018 ACR/ARHP Annual Meeting
Tapering of Biological Antirheumatic Drugs in Rheumatoid Arthritis Patients Is Achievable and Cost Effective in Daily Clinical Practice: DATA from the Brussels UCL RA Cohort
Stéphanie Dierckx¹, Bernard R. Lauwerys², Tatiana Sokolova¹, Laurent Meric de Bellefon¹, Maria Stoenoiu¹, Adrien Nzeusseu Toukap³, Frédéric A. Houssiau², Aleksandra Avramovska¹ and Patrick Durez¹, ¹Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Department of Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Several studies have demonstrated that Rheumatoid Arthritis (RA) patients achieving low disease activity or remission are able to taper biological disease-modifying antirheumatic drugs (bDMARDs).…
Abstract Number: 626 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Cycling Tumor Necrosis Factor Inhibitor (TNFi) Versus Swapping to a Nontnfi on Patient-Reported Functional Ability of Patients with Rheumatoid Arthritis
Maria A. Lopez-Olivo¹, Aliza Matusevich², Scott B. Cantor³, Gregory Pratt⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ³Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX
Background/Purpose: Data on patient-reported functional ability to evaluate the optimal strategy for patients who have failed to first TNFi is scarce. Patient-reported outcomes are a…
Abstract Number: 627 • 2018 ACR/ARHP Annual Meeting
Corticosteroid Utilization before and after Initiation of Biologic Dmards between Patients with Rheumatoid Arthritis
Burcu Yagız¹, Belkıs Nihan Coşkun², Sedat Kiraz³, Ihsan Ertenli⁴, Orhan Kucuksahin⁵, Ediz Dalkiliç⁶, Cemal Bes⁷, Nilufer Alpay Kanitez⁸, Timucin Kasifoglu⁹, Hakan Emmungil¹⁰, Pamir Atagunduz¹¹, Suleyman Serdar Koca¹², Muhammet Cinar¹³, Aşkın Ateş¹⁴, Servet Akar¹⁵, Onay Gercik¹⁶, Duygu Ersozlu Bakirli¹⁷, Veli Yazisiz¹⁸, Gezmis Kimyon¹⁹, Nazife Sule Yasar Bilge²⁰, Muge Aydin Tufan²¹, Ridvan Mercan²², Burak Oz¹², Zeynel Abidin Akar¹², Omer Karadag²³, Bahar Kelesoglu²⁴, Sedat Yılmaz²⁵, Sezin Turan²⁶, Yavuz Pehlivan², Ender Terzioglu²⁷, Levent Kilic²³, Sukran Erten²⁸, Koray Tascilar²⁹ and Umut Kalyoncu³⁰, ¹Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, ²Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ³Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ⁴Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ⁵Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, ⁶Department of Internal Medicine, Division of Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey, ⁷Department of Rheumatology, Health Sciences University Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁸Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey, ⁹Department of Internal Medicine, Division of Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ¹⁰Department of Internal Medicine, Division of Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, ¹¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ¹²Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ¹³Division of Rheumatology, Gülhane Military Medical Academy, School of Medicine, Ankara, Turkey, ¹⁴Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey, ¹⁵Department of Internal Medicine, Division of Rheumatology,, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, ¹⁶Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ¹⁷PsART study group, Adana, Turkey, ¹⁸Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹⁹Rheumatology, Hatay Mustafa Kemal University Faculty of Medicine, Hatay, Turkey, ²⁰Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ²¹Rheumatology, Cukurova University School of Medicine, Adana, Turkey, ²²Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ²³Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²⁴Rheumatology, Ankara University, Ankara, Turkey, ²⁵Division of Rheumatology, Gülhane Military Medical Academy, Faculty of Medicine, Ankara, Turkey, ²⁶Trakya University Medical Faculty, Edirne, Turkey, ²⁷Division of Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ²⁸PsART study group, Ankara, Turkey, ²⁹Rheumatology, Okmeydani Research and Training Hospital, Istanbul, Turkey, ³⁰Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory, systemic autoimmune disease that causes several health problems, such as pain, joint destruction and loss of function.…
Abstract Number: 628 • 2018 ACR/ARHP Annual Meeting
Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database
Elliot Hepworth¹, Mohammad Movahedi², Emmanouil Rampakakis³, Reza Mirza¹, Arthur Lau⁴, Angela Cesta⁵, Janet E. Pope⁶ and Claire Bombardier⁷, ¹Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴50 Charlton Avenue East, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: For patients with Rheumatoid Arthritis (RA) who do not achieve adequate clinical response with combined conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), the next…
Abstract Number: 629 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan
Song-Chou Hsieh¹, Yi-Hsing Chen², Wei-Sheng Chen³, Wen-Chan Tsai⁴, Jui-Chieh Hu⁵, Hsiang-Cheng Chen⁶, Jack Mardekian⁷ and Chacun Lai⁸, ¹National Taiwan University Hospital, Taipei, Taiwan, ²Taichung Veterans General Hospital, Taichung City, Taiwan, ³Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ⁵Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁶National Defense Medical Center & Tri-Services General Hospital, Taipei, Taiwan, ⁷Pfizer Global Biometrics & Data Management, NY, NY, ⁸Pfizer PFE Limited, New Taipei, Taiwan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib was approved in December 2014 for RA under Taiwan’s National Health…
Abstract Number: 630 • 2018 ACR/ARHP Annual Meeting
Is Treatment Adherence of RA Patients to Injectable MTX Influenced By Previous MTX Route of Administration?
René-Marc Flipo¹, Eric Senbel², Sonia Tropé³, Elena Zinovieva⁴, Agnès Courbeyrette⁵ and Hélène Herman-Demars⁴, ¹Hôpital Roger Salengro, Lille, France, ²Rheumatology office, Marseille, France, ³149 avenue du Maine, ANDAR, Paris, France, ⁴Medical Department Nordic Pharma, Paris, France, ⁵Medical Departement, Nordic Pharma, Paris, France
Background/Purpose: Previous studies have shown, that switching from oral to subcutaneous (SC) MTX can lead to improved efficacy and bioavailability (especially for doses ≥15mg/wk) as…
Abstract Number: 631 • 2018 ACR/ARHP Annual Meeting
A Self-Determination Theory Based Intervention to Promote Autonomous Motivation for, and Engagement in Physical Activity in Rheumatoid Arthritis: Theoretical Process Evaluation of a Randomised Controlled Trial
Sally A.M. Fenton^1,2, Jet J.C.S. Veldhuijzen van Zanten^1,2, George S. Metsios^2,3, Peter C. Rouse⁴, Nikos Ntoumanis⁵, Chen-An Yu⁶, George D. Kitas^1,2,7 and Joan L. Duda¹, ¹School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United Kingdom, ²Department of Rheumatology, Russells Hall Hospital, Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, ³Faculty of Education Health & Wellbeing, University of Wolverhampton, Walsall, United Kingdom, ⁴Department for Health, University of Bath, Bath, United Kingdom, ⁵Faculty of Health Sciences, School of Psychology, Curtin University, Perth, Australia, ⁶Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom, ⁷Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom
Background/Purpose: Moderate-to-vigorous physical activity (MVPA) is recommended for the treatment and management of physical and psychological health in Rheumatoid Arthritis (RA). However, most people living…
Abstract Number: 632 • 2018 ACR/ARHP Annual Meeting
Interpretation of Symptoms Should Take into Account Gender in Psoriatic Arthritis: An Analysis of 451 Patients
Clémence Gorlier¹, Laure Gossec², Deborah Puyraimond-Zemmour¹, Laura C. Coates³, Uta Kiltz⁴, Ying Ying Leung⁵, Penelope Palominos⁶, Juan D. Cañete⁷, Rossana Scrivo⁸, Andra Rodica Balanescu⁹, Emmanuelle Dernis¹⁰, Sandra Tälli¹¹, Adeline Ruyssen-Witrand¹², Martin Soubrier¹³, Sibel Zehra Aydın¹⁴, Lihi Eder¹⁵, Inna Gaydukova¹⁶, Ennio Lubrano¹⁷, Pascal Richette¹⁸, M. Elaine Husni¹⁹, Maarten de Wit²⁰, Josef S. Smolen²¹ and Ana-Maria Orbai²², ¹Sorbonne Université, PARIS, France, ²Rhumatologie, Médecine Sorbonne Université, Pitié-Salpétrière Hospital, Paris, France, ³University of Oxford, Oxford, United Kingdom, ⁴Rheumatology, Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁶Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁷Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, ¹²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ¹⁶North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, ¹⁷Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ¹⁸Rheumatology, Université Paris Diderot, Paris, France, ¹⁹Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²⁰Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, ²¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Treatments targets in psoriatic arthritis (PsA) are remission (REM) or Low Disease Activity (LDA) which are usually defined based on objective disease activity but…
Abstract Number: 633 • 2018 ACR/ARHP Annual Meeting
The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis
Dafna D Gladman¹, Wolf-Henning Boehncke², Alice B Gottlieb³, Philip Helliwell⁴, Peter Nash⁵, Xie L. Xu⁶, Stephen Xu⁶, Yuhua Wang⁶, Elizabeth C Hsia^6,7, Chetan S Karyekar⁶ and Atul A. Deodhar⁸, ¹Krembil Research Institute, U of Toronto, Toronto, ON, Canada, ²U of Geneva, Geneva, Switzerland, ³NY Medical College, Metropolitan Hospital, NY, NY, ⁴U of Leeds, Leeds, United Kingdom, ⁵U of Queensland, Brisbane, Australia, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷U Penn School of Medicine, Phila, PA, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: In a Ph2 study, GUS was shown to be safe&effective in pts w/active PsA. We evaluated effect of GUS on dactylitis in subset of…
Abstract Number: 634 • 2018 ACR/ARHP Annual Meeting
Spinal Mobility Measures Allow Discrimination of Subgroups of Different Activity and Severity in Early Axial Spondyloarthritis
Mary Lucy Marques^1,2, Sofia Ramiro^2,3, Floris van Gaalen², Philippe Goupille⁴, Maxime Dougados⁵ and Désirée van der Heijde⁶, ¹Rheumatology, Centro Hospitalar e Universitário de Coimbra, Portugal & Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Zuyderland Medical Center, Heerlen & Leiden University Medical Center, Leiden, Netherlands, ⁴Université François-Rabelais, Tours, France, ⁵Department of Rheumatology, Paris Descartes University and Cochin Hospital, Paris, France, ⁶Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Spinal mobility has been mostly investigated in cohorts of patients with established AS. However, it was scarcely studied in the early phases of the…
Abstract Number: 635 • 2018 ACR/ARHP Annual Meeting
Measuring Spinal Mobility over Time in Early Axial Spondyloarthritis: Can We Do It Reliably?
Mary Lucy Marques^1,2, Sofia Ramiro^3,4, Floris van Gaalen², Philippe Goupille⁵, Maxime Dougados⁶ and Désirée van der Heijde⁷, ¹Rheumatology, Centro Hospitalar e Universitário de Coimbra, Portugal & Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands, ⁴Zuyderland Medical Center, Heerlen & Leiden University Medical Center, Leiden, Netherlands, ⁵Université François-Rabelais, Tours, France, ⁶Department of Rheumatology, Paris Descartes University and Cochin Hospital, Paris, France, ⁷Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: The use of spinal mobility measures (SMMs), at the individual level and in the follow-up of patients with early axSpA has not yet been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].